ClinicalTrials.gg
RecruitingNCT06224673Updated Jun 11, 2026

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

A Phase 2 interventional study of ARX788 and Computed Tomography (CT) in HER2 Low Breast Carcinoma, Triple Negative Breast Cancer and Hormone-receptor-positive Breast Cancer, sponsored by Laura Huppert, MD, BA. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Laura Huppert, MD, BA · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
376th of 605
36 · median 52
Started
2026
with 37 others
Phase 2
191 of 645
45 open now
Primary completion
2029-11
later than 228 of 262 live
Registered
525th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 376th largest by planned enrollment of the 605 interventional ones that give a count, is one of 38 that started in 2026, is one of 191 in phase 2, reaches primary completion later than 228 of the 262 other live ones, and was the 525th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

153 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the objective response rate (ORR) of participants with HER2-low locally advanced unresectable/metastatic breast cancer on ARX788 monotherapy.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of ARX788 monotherapy in participants with HER2-low locally advanced unresectable or metastatic breast cancer (MBC) as measured by duration of response (DOR), best overall response (BOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

II. To evaluate the safety of ARX788 monotherapy in participants with HER2-low locally advanced unresectable or MBC.

III. To evaluate the safety, tolerability, adherence, and feasibility of the eye toxicity prevention regimen in the ocular toxicity prevention sub study.

IV. To evaluate the efficacy of the eye toxicity prevention regimen in the ocular toxicity prevention sub study.

EXPLORATORY OBJECTIVES:

I. Biomarker analyses to evaluate association of efficacy measures with potential biomarkers (e.g., via assessment of circulating tumor deoxyribonucleic acid (ctDNA), single cell ribonucleic acid (RNA) sequencing, etc.).

II. Patient-reported outcomes (PROs) of patients on ARX788 monotherapy.

III. To determine the pharmacokinetics (PK) of ARX788 in tears.

OUTLINE:

Participants are assigned to cohorts based on breast cancer subtype and receive ARX788 intravenously (IV) over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. The first 5 participants successfully enrolled will receive topical amiloride 0.1% to evaluate early safety, tolerability, adherence, and feasibility data. Participants may continue study treatment until progressive disease, intolerable side effects, discontinuation due to Investigator's clinical judgment, discontinuation due to patient's choice, or the Sponsor-investigator's decision to stop the study. After completion of study treatment, participants are followed up at 30 days and then every 12 weeks for 1 year.

03

Conditions studied

  • HER2 Low Breast Carcinoma
  • Triple Negative Breast Cancer
  • Hormone-receptor-positive Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma

Keywords

  • Antibody-drug Conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants age 18 years or greater with ability to provide written for the study.
  • (ECOG) score of 0-2.
  • Estimated of at least at 6 months per investigator assessment.
  • Ability to understand and the willingness to sign a written informed consent document.
  • documented -low locally advanced unresectable or breast cancer (MBC). NOTE: human epidermal growth factor receptor 2 (HER2)-low status determined by HER2 immunohistochemistry (IHC) 1+ or 2+ and no evidence of HER2 gene amplification by in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), which can be documented from any tumor sample during the patient's cancer treatment history (early-stage or metastatic).

    • Cohort 1: Participants with hormone receptor positive (HR+)/HER2-low locally advanced unresectable or MBC. HR+ status defined as estrogen receptor >= 10% and/or progesterone receptor ≥ 10% and HER2 low.
    • Cohort 2: Participants with hormone receptor negative (HR-)/HER2-low locally advanced unresectable or MBC. Considered HR- if estrogen receptor (ER) and progesterone receptor (PR) \< 10% and HER2-low.
  • Presence of at least one per (RECIST) version (v) 1.1. NOTE: Participant's with at least one measurable lytic bone lesion are eligible.
  • Availability of tumor block or formalin-fixed paraffin-embedded (FFPE) tissue as 10 precut unstained slides will be collected for the HER2 status evaluation and biomarker analysis based on the most recent tumor tissue sample. NOTE: New pretreatment tissue is preferred as HER2 status may change, but a fresh biopsy is not required. The study team and investigator will make every attempt to get archival tissue. Participants who do not have archival or new tumor tissue available may be eligible after discussion with the study principal investigator (PI).
  • Participants with stable and treated are eligible if the participants meet the following criteria:

    • Prior stereotactic radiosurgery (SRS) should be completed >=7 days before study treatment initiation.
    • Prior whole-brain radiation therapy should be completed >=14 days before study treatment initiation.
    • Any ongoing use of systemic does not exceed 2 mg of dexamethasone (or equivalent) daily.
  • Participants must have received at least one or ADC therapy for locally advanced unresectable or metastatic disease. Prior therapy is allowed.
  • ≥ 8.0 g/dL
  • ≥ 1.0 x 10\^9/L
  • ≥ 100,000 x 10\^9/L
  • Total ≤ 1.5 x institutional , unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits
  • (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) \< 3 x institutional upper limit of normal. In participants with liver metastases, \<= 5 x institutional upper limit of normal is allowed.
  • Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) \< 3 x institutional upper limit of normal. In participants with liver metastases, \<=5 x institutional upper limit of normal is allowed.
  • Creatinine ≤ 1.5 x within institutional upper limit of normal OR (GFR) ≥ 50 mL/min/1.73 m, calculated using the Cockcroft-Gault equation
  • Adequate cardiac function as assessed by ≥ 50% or institutional lower limit of normal.
  • (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy.
  • Individuals with a history of virus (HCV) infection must have been treated without detectable HCV RNA.
  • Participants must have recovered from all acute toxicities from prior therapies to ≤ grade 1 or baseline (except for alopecia and neuropathy) per the National Cancer Institute (NCI)- (CTCAE) v 5.0.
  • Male and female subjects of reproductive/ must agree to use a highly effective form of or total sexual abstinence during and upon completion of the study; and for at least 3 months after the last dose of study drug for women of childbearing potential (WOCBP) and at least 5 months after the last dose of study drug for men whose partners are WOCBP.
  • Male subjects must agree to not freeze or donate sperm starting at Screening and throughout the study period, and at least 5 months after the final study drug administration.
  • Female subjects must agree to not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 3 months after the final study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Has a prior history of treatment with ARX-788 or auristatin analogues.
  • Has a history of allergic reaction to any component of ARX788.
  • Has exposure to any other or commercial anti-cancer agents or therapies administered with the intention to treat within 14 days before the first dose of study treatment. NOTE: Anti-hormonal therapy may be administered up to 7 days prior to the first dose of study treatment.
  • Radiotherapy outside of the brain administered \<7 days prior to first dose of ARX788
  • Prior or current history of interstitial lung disease (ILD), pneumonitis, or other lung disease with the exception of disease that is directly attributable to the presence of lung from their underlying cancer.
  • Participants with significant pulmonary conditions, defined as any of the following:

    • Any prior history of drug-induced immune-mediated pneumonitis.
    • Prior history of radiation therapy to the chest of > 18 gray (Gy) with residual sequelae considered clinically significant by investigator assessment.
    • Radiographic evidence of radiation fibrosis involving > 15% of the lung parenchyma associated with clinical symptoms.
    • Any requirement for supplemental oxygen.
  • Clinically-significant ocular findings including history of keratitis, keratopathy, and/or active eye disease (excluding glaucoma).
  • History of congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or myocardial infarction within 6 months prior to enrollment. prolongation of >470 msec (females) or >450 msec (males) based screening .
  • Has a diagnosis of . NOTE: Stable are allowed.
  • Has an active systemic or psychiatric illness that would impact the patient's ability to receive study therapy.
  • Has an uncontrollable intercurrent illness, infection (including participants with active, symptomatic Coronavirus disease of 2019 (COVID-19) infections), or other conditions that could limit study compliance or interfere with study assessments.
  • Has a history of an additional malignancy that is progressing or has required active treatment within the past 3 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ (excluding carcinoma in situ of the bladder or high-grade cervical dysplasia in the last three years), and thyroid cancer not requiring cytotoxic agents that have undergone potentially curative therapy are not excluded.
  • Pregnancy or breastfeeding.
  • Has an active, uncontrolled , , and/or (HIV) infection. Participants with adequately controlled hepatitis B, hepatitis C, and/or HIV are allowed. NOTE: HIV and hepatitis B and C testing are not required for screening. Testing will only be done if clinically indicated.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cohort 1: HR+/HER2-low

    Participants with locally advanced, unresectable MBC that is hormone receptor (HR) positive (HR+) /human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.

    Drug: ARX788 · Procedure: Computed Tomography (CT) · Procedure: Biospecimen Collection

  • Experimental
    Cohort 2: HR-/HER2-low

    Participants with confirmed HR negative (HR-)/human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.

    Drug: ARX788 · Procedure: Computed Tomography (CT) · Procedure: Biospecimen Collection

  • Experimental
    Ocular Toxicity Prevention Sub-study

    The first 5 participants from Cohorts 1 and 2 will be given outpatient eye drops to use from home in conjunction with ARX788. Participants will be drop applied to each eye 4 times a day starting on the day of first infusion and continuing daily throughout treatment and for 30 days after the last infusion.

    Drug: ARX788 · Procedure: Computed Tomography (CT) · Procedure: Biospecimen Collection · Drug: Amiloride

Interventions

  • DrugARX788

    Given IV

    Also known as: Anvatabart Opadotin, Antibody-drug Conjugate ARX788, Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788, Anti-Her2 ADC

  • ProcedureComputed Tomography (CT)

    Undergo CT or Positron Emission Tomography(PET)/CT

    Also known as: CT Scan, PET/CT

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Specimen Collection, Biological Sample Collection

  • Ophthalmologic drops given topically to participants for an eye toxicity substudy

    Also known as: Amiloride Topical Eye Drops

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) is defined as the proportion of participants who experience complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR and corresponding two-sided exact 90% confidence intervals will be reported.

    Time frame: Up to 1 year

Secondary outcomes

  1. Duration of response (DOR)

    Duration of response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for participants with a BOR of CR or PR. Medians and corresponding two-sided 95% confidence intervals will be reported.

    Time frame: Up to 1 year

  2. Overall Best Response (BOR)

    Best overall response (BOR) is defined as the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

    Time frame: Up to 1 year

  3. Disease Control Rate (DCR)

    The Disease control rate (DCR) is defined as the sum of PR, CR and stable disease (SD) divided by the number of response evaluable participants All-Subjects-as-Treated(AsaT).

    Time frame: Up to 1 year

  4. Median Progression Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable participants (AsaT). Medians and corresponding two-sided 95% confidence intervals will be reported.

    Time frame: Up to 2 years

  5. Median Overall Survival (OS)

    Overall survival (OS) is defined as the amount of time that elapses between the initiation of therapy (Cycle 1, Day 1 (C1D1) and the time of death from any cause. Medians and corresponding two-sided 95% confidence intervals will be reported.

    Time frame: Up to 2 years

  6. Proportion of participants with treatment-emergent adverse events (AEs)

    Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

    Time frame: Up to 1 year

  7. Percentage of participants adhering to the eye drop

    Tolerability and adherence to eye toxicity prevention regimen will be reported as the percentage of participants who adhered to the regimen during the course of the study.

    Time frame: Up to 1 year

  8. Mean score on an eye pain scale

    After each drop, participants will assess the amount of pain on a scale from 1 (lowest amount) to 10 (greatest amount). The mean and standard deviation of the pain scores by cohort will be reported

    Time frame: Up to 1 year

  9. Proportion of participants reporting ocular adverse events

    The proportion of participants with a recorded grade \>=2 ocular AEs based on visual acuity, eye symptoms, cornea evaluation and intraocular pressure (mmHg) readings will be reported.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2029, 41 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 41 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartActual
Jun 5, 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224673
Lead sponsor
Laura Huppert, MD, BA
Collaborators
Ambrx, Inc.
Responsible party
Laura Huppert, MD, BA (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Jan 25, 2024
Start date
Jun 5, 2026
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Amy Langdon
Contact
amy.deluca@ucsf.edu
(415) 353-7288
Laura Huppert, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARX788

Start the discussion